Brief: Ose Immunotherapeutics Provides Preclinical Updates On Clec-1 Myeloid Immune Checkpoint

Ose Immunotherapeutics SA

20/04/2023 06:40

April 20 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * PRESENTS ADDITIONAL PRECLINICAL UPDATES ON CLEC-1, A NOVEL
MYELOID IMMUNE CHECKPOINT IN IMMUNO-ONCOLOGY
    * OSE IMMUNOTHERAPEUTICS PRESENTS ADDITIONAL PRECLINICAL
UPDATES
ON CLEC-1, A NOVEL MYELOID IMMUNE CHECKPOINT IN IMMUNO-ONCOLOGY
    * TRIM21 IDENTIFIED AS A NOVEL INTERACTION PARTNER FOR
CLEC-1, AND
CLEC-1/TRIM21 AXIS AS A NEW TARGET FOR CANCER IMMUNOTHERAPY
    * CLEC-1 INHIBITORY MYELOID CHECKPOINT BLOCKADE ENHANCES
ANTITUMOR
RESPONSES AND TUMOR PHAGOCYTOSIS BY MACROPHAGES

Source text for Eikon:  ID:nBwbXG3gZa 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))